NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is a better way to control the multiple myeloma than chemotherapy and AHCT alone.
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborator
Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT04635735
Official Title: A Phase I/II Trial of Ipilimumab After CD34-Selected Allogeneic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
First Posted : November 19, 2020
Click here to see details on ClinicalTrials.gov
Drug: Ipilimumab
Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
Ipilimumab (Code C2654)
Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
BMS-734016
Ipilimumab
ipilimumab
IPILIMUMAB
Ipilimumab Biosimilar CS1002
MDX-010
MDX-CTLA4
Yervoy
Locations
United States, New Jersey
United States, New York